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Abstract
Background: Travellers’ diarrhoea (TD) is the most frequent health problem among travellers to the tropics. Using
routine techniques, the aetiology mostly remains unresolved, whereas modern molecular methods enable reducing
the number of equivocal cases considerably. While many studies address the aetiology of TD in Asian, Central
American and North African tourist resorts, only few focus on Western Africa.
Methods: Stool samples from 45 travellers travelling in Benin, West Africa, were analyzed by a new multiplex qPCR
assay for Salmonella, Yersinia, Campylobacter, Vibrio cholerae, Shigella or enteroinvasive (EIEC), enterohaemorrhagic
(EHEC), enterotoxigenic (ETEC), enteroaggregative (EAEC), and enteropathogenic Escherichia coli (EPEC).
Results: All 18 pre-travel samples proved negative for bacterial pathogens. Of the 39/45 (87%) travellers having had
TD, EPEC was detected in post-travel samples in 30 (77%) cases, EAEC in 23 (59%), ETEC in 22 (56%), Shigella or EIEC
in 7 (18%), EHEC in two (5%), and Salmonella in one (3%). In 31(79%) of the TD cases two or more bacterial pathogens
were identified. Two (8%) samples remained negative: both patients had taken antimicrobials for TD.
Conclusions: EPEC, EAEC and ETEC were the most common findings. 79% of the cases had a co-infection. As modern
diagnostics reveals in most patients a multitude of pathogens, the role of each pathogen should be re-evaluated.
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Background
Travellers’ diarrhoea (TD) has been estimated to be
contracted by 80 million individuals every year [1], yet
the causative agents often remain poorly characterized.
Although TD appears to be of bacterial origin in as
many as 75% of the cases [2,3], the causative micro-
organism is left unidentified in up to half of those re-
ported [2-5]. When using modern PCR-based methods,
diarrhoeagenic E. coli has been detected in one third of the
culture-negative stool samples [6]. Recently, researchers
employing more advanced diagnostic techniques have suc-
ceeded in decreasing the number of unexplained TD cases
to 5-24% [1,7,8].
Enterotoxigenic Escherichia coli (ETEC) has been consid-
ered the most common causative agent for TD worldwide
[2,3]. With improved methodology, however, enteroaggre-
gative E. coli (EAEC) has been reported even more often
than ETEC [1,8,9]. According to some recent studies
[1,7,8], multiple pathogens are detected more frequently
(up to 60% of cases) than anticipated before.
In many laboratories the methods available for routine
clinical analyses will only identify Salmonella, Campylo-
bacter, Shigella and Yersinia, and Clostridium difficile
or certain variants of EHEC are investigated on separate
request. This approach leaves all patients having the
most common TD pathogen, diarrhoeagenic E. coli,
without accurate bacteriological explanation for their
disease. We have recently described a new multiplex
qPCR method which allows rapid detection of nine diar-
rhoeal pathogens at the same time [1]. This method was
adopted into routine use at our laboratory in 2012.
While earlier microbial research centred on travellers
to Southeast Asia, South Asia, Central America, and
Northern Africa [3], other parts of Africa have been
given scarce attention. We know of merely five studies
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[8,10-13], just two [8,13] of them from this century, de-
scribing the aetiology of TD in travellers to Central or
Western Africa. In these reports the percentage of unex-
plained cases ranges between 5 and 60.
The present study looks into the aetiology of TD using
modern methods and focusing on a group travelling to-
gether under similar conditions in a non-touristic destin-
ation in Sub-Saharan Africa.
Methods
Study population/recruitment
The participants were recruited from among 96 travel-
lers (Figure 1) destined for Grand Popo, Benin, West
Africa in November 2009. They were each given ques-
tionnaires and test tubes for stool samples either at an
information session or a health care appointment before
the journey; they also received brochures on pertinent
health issues, including detailed instructions on prevent-
ive measures against TD. The participants were asked to
provide stool samples prior to departure and on return,
and to fill in the questionnaires before (Q1) and immedi-
ately after (Q2) the trip, and a third one (Q3) three
weeks later. As the initial number of volunteers provid-
ing Q1 and pre-travel stool samples proved quite low
(20/96), the researchers went to meet the returning trav-
ellers at the airport not only to remind the volunteers of
the study but also to ask for new ones to participate. On
that occasion 44 new subjects were included in the
research despite lacking pre-travel samples, 17 of whom
failed to return both stool sample and questionnaire. Of
the initial 20 participants who had provided the first faecal
sample before the journey, two (10%) did not give the
second one after it. The 19 subjects (2 recruited at start,
17 at airport) failing to provide post-travel samples were
considered dropouts. Of the 45 who gave a second stool
sample and answered Q2, 27 also returned Q3. Thus, 18
pre-travel and 45 post-travel samples were analyzed for
pathogens with qPCR.
The journey in brief
The group travelled together for 9 days before returning
to Finland. They were accommodated at a residence and
three nearby hotels. Meals were eaten in smaller groups
at local restaurants.
Definition and classification of travellers’ diarrhoea
Travellers’ diarrhoea was defined according to the WHO
criteria [14] as the passage of 3 or more loose or liquid
stools per day, or more frequently than is normal for the
individual. Severe TD was defined as six or more un-
formed diarrhoeal stools per 24 hours or diarrhoea ac-
companied by fever or containing blood, or requiring
hospitalization, and mild TD as 1–2 unformed daily stools.
Cases not fulfilling these criteria were classified as moder-
ate. Diarrhoea was defined as travel-related had it begun
abroad or within seven days after returning home.
The questionnaires
The subjects filled in three questionnaires: pre-travel ques-
tionnaire (Q1) covered demographic particulars, current
medical conditions, knowledge about travel-related risks,
vaccination status and possible diarrhoeal symptoms at
the time of first (pre-travel) faecal sample. Questionnaire 2
(Q2) was collected on return to Finland. The questions in
Q2 concerned diarrhoeal and other symptoms during and
just after the trip, medications taken over its course, risk
behaviour, and contacts with local health care. The third
questionnaire (Q3) collected three weeks after return was
a follow-up focusing on symptoms over the first three
weeks at home, possible medications, and contacts with
health care.
Adherence to TD prevention advice was measured in
Q2 by the following questions: “Did you drink tap water,
purified water or bottled water?”, “Did you eat cold
salads”, “Did you eat uncooked meat or fish?”, “Did you
always/often/seldom wash hands before eating?” and
“Did you use utensils/bare fingers?”
Collection of stool samples
The volunteers were asked to give a pre-travel stool
sample within one week before departure and a post-
travel sample from the first (or second) stool passed
after returning home. The samples were collected as
swabs in Copan M40 Transystem tubes (Copan Diagnos-
tics, Brescia, Italy) and sealed in special mailing enve-
lopes. As the group returned to Finland on a Saturday
evening, they were advised to refrigerate their post-travel
samples and mail them only on Monday morning; the
samples thus reached the laboratory in 1–3 days. There
the swabs were frozen in −20°C for later analysis.
Figure 1 The study protocol.
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Nucleid acid extraction
The extraction process and qPCR have been recently
described in detail [1]. Briefly, total nucleid acids were
extracted using the standard semi-automated protocol
of easyMAG (bioMérieux, Marcy-l’Etoile, France). The
swap was thawed and directly inoculated into 2 mL of lysis
buffer, and processed according to manufacturer’s instruc-
tions. A general extraction protocol with 25 μL elution
volume was performed. A 0.5 μL of eluted template was
utilized per each qPCR reaction in 20 μL final volume.
qPCR analysis of bacterial pathogens
The analyses were carried out with a multiplex qPCR
method [1] which covers the following pathogens: diar-
rhoeagenic E. coli including EPEC, ETEC, EAEC, EHEC
and EIEC or Shigella as well as Salmonella, Yersinia,Vibrio
cholerae, and Campylobacter spp. This assay described in
detail recently [1] allows a rapid and simultaneous exam-
ination of all these pathogens, providing results in just
four hours.
We also investigated the bundle-forming pilus struc-
tural gene (bfpA) linked to the virulence of typical EPEC.
The gene was amplified using the primers F_bfpA_001
CTGTCTTTGATTGAATCTGCAATGG and R_bfpA_
001CTGAAATAGCATTCTGTGACTTATTGG. The de-
tection was performed with the Stratagene MxPro
3005P instrument (Agilent Technologies, Inc., CA) util-
izing SYBR Green chemistry (Thermo Fisher Scientific,
Finland) by a standard two-step protocol with melting
curve analysis. Briefly, initial denaturation time of 15 min
was followed by 45 cycles of denaturation at 94°C for 1 mi-
nute, and annealing/extension at 60°C for 1 min. The PCR
amplicon was confirmed correct by Sanger sequencing
and characteristic melting temperature.
Statistical analysis
Differences between the various traveller groups were
examined by Chi-square tests using SPSS 19.0.0.1 (SPSS
Inc., Chicago, IL, USA).
Ethical clearance and informed patient consent
This study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and the protocol
approved by the Ethics Committee of the Department of
Medicine in Helsinki University Central Hospital. Written
informed consent was obtained before enrolment from all
patients and volunteers, and legal caretakers of minors.
Results
Demographics of the study population
Background information on the volunteers is provided
in Table 1. Of the 45 study subjects, 27 (60%) were
female. The average age was 46 years (range 15 – 68 years).
Seven had medication for an underlying chronic illness
(hypertension, diabetes, hypercholesterolaemia).
GI and other symptoms in the study population
Of the 45 subjects, 39 (87%) had contracted TD over the
journey (Figure 1). 14 (36%) cases proved severe, 19 (49%)
moderate, and 6 (15%) mild. Severe TD was accompanied
by fever in 11/39 (28%) cases. Only two reported having
contacted local healthcare, and none was hospitalized. TD
started on average on the 6th day of travel, and in 50% of
the cases the symptoms lasted for over three days. Of the
18 initially recruited who had returned both pre- and
post-travel samples, 12 (67%) had developed TD and six
(33%) had remained asymptomatic, whereas all the 27 re-
cruited at the airport had had TD over the journey. 37/39
volunteers (95%) had ongoing symptoms at the time of
sampling. The third questionnaire (Q3) was returned by
27 study subjects: two with TD (7%) still had slightly loose
stools, 22 (81%) no longer had any symptoms, and three
(11%) initially asymptomatic had not developed symptoms
over the follow-up either.
Microbiological findings
All 18 pre-travel samples were tested negative for the
nine bacterial pathogens. The results of post-travel sam-
ple analyses are provided in Table 2. Only 3/45 post-
travel stools proved negative. 35/45 (78%) subjects were
identified to have contracted two or more pathogens;
31/39 (79%) of those with TD had multiple pathogens.
EPEC (76%) was the most common finding followed by
EAEC (60%) and ETEC (56%). No differences were found
between symptomatic and asymptomatic subjects in the
relative proportions of the various pathogens. 11/34 (32%)
of EPEC strains proved bfpA-positive.
Antimicrobial medications
Data on the use of antimicrobials are provided in Table 3.
Consistent with the Finnish recommendations [15], none
of the travellers had used antimicrobials for prophylaxis
of TD.; 22 had taken doxycycline as antimalarial chemo-
prophylaxis. Six (15%) subjects had taken antimicrobials
against TD during the trip: 4 had used ciprofloxacin for
1–3 days, one azithromycin for 2 days and one penicillin
(sic!), but did not report the number of days. After
returning home, 8 more took a course of antimicrobial
medication. Two were prescribed ciprofloxacin at the
travel clinic 3–10 days after the journey, as their symp-
toms had not resolved; four with ongoing symptoms had
EIEC/Shigella in their stool samples, and were treated
with ciprofloxacin, adhering to the Finnish recommen-
dation that all Shigella cases need to be treated because
of its low infectious dose; one took ciprofloxacin for a
urinary tract infection; one already asymptomatic self-
administered ciprofloxacin despite being told that no
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medication was needed for the EAEC detected in her
post-travel stool sample.
Risk behaviour among the subjects
The travellers considered themselves aware of all the
health-related risks e.g. malaria and TD, and most of
them had been vaccinated according to national recom-
mendations [16]. Despite this, not more than 31% of the
subjects with TD and 33% of the asymptomatic actually
followed all TD prevention advice (see Table 4).
Discussion
In addition to providing a wide-range analysis of bacter-
ial pathogens in TD, the present study contributes to the
limited knowledge of diarrhoeal pathogens in travellers
to West Africa.
There are no previous reports of TD in tourists to
Benin, and very few of travellers to West Africa [8,10-13]
One of the noteworthy findings was the exceptionally high
incidence of TD among our study subjects. Although
Sub-Saharan Africa is generally presented as an area with
Table 1 Background data of 45 travellers to Benin, West Africa
Yes
n (%)
No
n (%)
Data not available
n (% of all)
Sex: female (%) 27 (60) 18 (40) 0
Self-reported good knowledge about travel-related risks (Q1) 34 (77) 0 11 (23)
Underlying chronic disease (Q1) 7 (16) 38 (84) 0
Appropriate antimalarial prophylaxis* (Q2) 42 (93) 2 (4) 1 (2)
Pre-travel vaccination status (Q1)
Yellow fever* 40 (89) 0 5 (11)
Tetanus + diphtheria* 36 (80) 0 9 (20)
Polio* 21 (64) 12 (36) 12 (27)
MMR*,** 19 (42) 1 (2) 15 (33)
Hepatitis A* 39 (87) 0 6 (13)
Typhoid fever*** (either peroral or injectable) 4 (9) 10 (22) 31 (69)
Meningococcal*** (type not specified) 2 (4) 9 (20) 34 (76)
Cholera*** 3 (7) 10 (22) 32 (71)
*National guidelines recommend to all travellers to Benin [16].
**Either has a history of mumps, measles and rubella or has received two doses of MMR vaccine.
***Vaccinations according to risk assessment [16].
Table 2 Bacteriological findings related to TD symptoms over the course of the journey in 45 travellers
All n = 45
(% of all)
Asymptomatic
n = 6 (% of these)
TD n = 39
(% of these)
Fever n = 11
(% of these)
EPEC 34 (76) 4 (67) 30 (77) 6 (55)
EAEC 27 (60) 4 (67) 23 (59) 7 (64)
ETEC 25 (56) 3 (50) 22 (56) 6 (55)
EIEC/Shigella 7 (16) 0 7 (18) 5 (45)*
EHEC 2 (4) 0 2 (5) 0 (0)
Salmonella 1 (2) 0 1 (3) 0 (0)
Campylobacter 0 0 0 0
Vibrio cholerae 0 0 0 0
Yersinia spp 0 0 0 0
No pathogen 3 (7) 0 3 (8) 1 (9)
Single pathogen 7 (16) 2 (33) 5 (13) 2(18)
Multiple pathogens 35 (78) 4 (67) 31(79) 8 (73)
3 or more pathogens 15 (33) 1 (17) 14 (36) 4 (36)
All subjects with fever also had TD. The figures are given separately for each traveller, and for the groups with or without TD. Differences between the two groups
were analyzed with Chi-square tests and indicated with asterisks when proved significant.
All differences were statistically insignificant except *p = 0,006.
Lääveri et al. BMC Infectious Diseases 2014, 14:81 Page 4 of 7
http://www.biomedcentral.com/1471-2334/14/81
a 20 – 60% risk for TD [17-20], 87% of our travellers re-
ported having contracted the disease. However, part of our
group were recruited at the airport only after the journey.
All these volunteers had TD and, in fact, their symptoms
appeared somewhat more severe than those of the pro-
spectively recruited TD patients (data not shown); the
symptoms presumably encouraged them to take part in
the study. The actual proportion of patients with TD
should, therefore, be evaluated from those who agreed to
participate at baseline: 60% (12/20) of them had TD. Inter-
estingly, the proportion of cases with ETEC appeared
higher among those recruited at the airport (67%) than
those enrolled prospectively (33%), correlating with the
exceptionally virulent nature of ETEC and severity of
symptoms.
In addition to the incidence of TD being high among
our travellers, one third of the cases proved severe. Their
proportion appears higher than reported elsewhere, yet
the criteria for severe disease vary between studies
[18,19]. The severity of the clinical picture presumably
explains the comparatively high (15%) use of antimicro-
bials for TD over the journey and also afterwards (18%
for TD). In two recent investigations conducted among
Dutch [18] and Swiss [19] travellers, only 5 and 7% used
antimicrobials for TD, yet, in these studies only 4 and
8% of the TD cases were considered severe.
Even though the travellers considered themselves
well-informed of TD as a health risk, barely one third of
them followed the TD prevention advice given. The
high number of TD cases among these travellers could
be ascribed to this, yet poor adherence is very common
(60 – 95%) among tourists in general [18,20-22]. More-
over, even strictly followed preventive measures appear
not to succeed in preventing TD [18-22].
While traditional routine diagnostics in most countries
only covers a few bacterial pathogens, modern PCR
methods have become increasingly applicable alongside
[1]. Indeed, our assay has been successfully used in rou-
tine diagnostics of TD in the Helsinki capital area since
2012. As obvious, even these approaches cannot be
designed to cover more than a limited number of patho-
gens. Some authors [7] have suggested that the unre-
solved TD cases could be ascribed to microbes earlier
not recognized as causing TD. In our study using mod-
ern diagnostic methods, the proportion of unexplained
TD was as low as 8%. Furthermore, the two TD patients
with negative stool samples had taken a course of cipro-
floxacin and had their symptoms go away by the time of
the stool sampling. We thus identified a pathogen in all
patients with symptoms at the time of sampling. The
data are consistent with earlier studies where PCR-based
methods have substantially decreased the number of
unexplained cases [1,6,8].
The selection of TD pathogens contracted in Benin
was of special interest. A large variety of pathogens was
detected with the various diarrhoeagenic E. colis as the
most prevalent findings. Among the nine bacteria stud-
ied, EPEC, EAEC and ETEC proved most frequent,
followed by EIEC/Shigella and Salmonella. No cases with
Table 3 Medication used by travellers during the journey
TD group n =39
(% of these)
Asymptomatic group
n = 6 (% of these)
Loperamide 19 (49) 0 (0)
Probiotics* (p = 0,632) 18 (69) 4 (66)
Proton Pump Inhibitors
(p = 0,292)
2 (5) 1 (17)
Anticrobial medication
during travel (excluding
doxycycline)
6** (15) 0 (0)
Anticrobial medication
after travel (excluding
doxycycline)
8*** (21) 0 (0)
Doxycycline as antimalarial
(p = 0,349)
18 (46) 4 (67)
The figures are given separately for those with or without TD. Differences
between these two groups were statistically insignificant when analyzed with
chi-square tests.
*Information missing from 13 travellers; % calculated on the basis of data
from others.
**4 took ciprofloxacin, 1 azithromycin and 1 penicillin (sic!).
***all took ciprofloxacin, one for UTI, 7 for TD.
Table 4 Adherence to TD prevention advice
TD group n = positive/information
available (% of these)
Asymptomatic group n = positive/information
available (% of these)
Ignored any “TD prevention advice” 28/38 (69) 4/6 (67)
Drank only bottled water 38/39 (97) 6/6 (100)
Ate cold salads 24/38 (63) 4/6 (67)
Ate uncooked meat or fish 3/15 (20) 1/2 (50)
Consumed alcohol 3 or more units/day 19/33 (58) 4/6 (67)
Ate without utensils (bare fingers) 10/39 (26) 2/6 (33)
Washed hands only seldom 3/39 (8) 1/6 (17)
The figures are given separately for those with and without TD. Differences between the two groups were statistically insignificant when analyzed with
Chi-square tests.
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Vibrio cholerae, Yersinia or Campylobacter were found.
Campylobacter, although common in Southeast Asia and
Nepal [3,5,23,24], has not been considered a major
pathogen in West Africa in previous reports either
[8,10-13,24]. Vibrio cholerae and Yersinia are rare in TD
everywhere. Little is known about the aetiology of child-
hood diarrhoea in Benin; no data from there was in-
cluded even in a recent report centring on Africa and
Asia [25]. Molecular biology methods are not currently
feasible for routine diagnostics in developing countries,
yet periodic microbial surveillance for diarrhoea is con-
sidered a necessity today [25,26].
It is noteworthy that, while EPEC is one of the most
frequent findings in childhood diarrhoea in developing
countries [27], its significance as a TD pathogen among
adults has not been confirmed [5,28]. In our patients, of
whom all but one were adults, 32% of the EPEC strains
proved bfpA-positive by PCR, and were thus considered
to represent typical EPEC serotypes [25,27]. No differ-
ence was seen in the occurrence of bfpA between those
with and those without symptoms, yet, despite the high
number of EPEC cases, there was only one TD with
EPEC as the sole pathogen. It should be pointed out that
some atypical EPEC strains harbour the bfpA gene, even
though they do not express the pili [29]. It was not
possible to systematically analyse the expression of a
functional pilin in the current material afterwards. The
expression is sensitive to in vitro conditions, and a care-
fully controlled study setup is required to confirm its
presence [29]. Until now, typical EPEC has been con-
sidered to affect only children up to two years of age
[25,27]. The molecular characteristics of EPEC asso-
ciated with diarrhoea in adult travellers should be ex-
plored separately.
An impressive finding was the multitude and variety of
pathogens in the faecal samples: in 78% of the travellers’
specimens two or more bacterial pathogens were iden-
tified, four of them with up to four pathogens. These
findings can evidently be ascribed both to a substantial
exposure to contaminated foods and the effective diag-
nostic methods used. The results accord with some pre-
vious reports [7,8,28] as well as our recent research [1],
where 20- 60% of travellers to varying destinations have
proved to carry multiple pathogens. Indeed, we also iso-
lated bacterial pathogens in the stools of the small group
of asymptomatic travellers: 67% had two or more bac-
terial pathogens, one had even four. The low number of
asymptomatic participants (merely six) does not allow
any definite conclusions from these data; an abundance
of bacterial pathogens in asymptomatic travellers has,
however, recently been reported in two other studies
[5,8]. It should be pointed out that the stools of our
volunteers were also explored for parasites with a
newly developed qPCR method which has not been
published as yet. The analysis showed that none of
the volunteers had Giardia lamblia, Cryptosporidium
parvum, or Entamoeba histolytica in their post-travel
specimens (Juha Kirveskari, personal communication).
The major limitation of the present investigation was
its low number of travellers. Nonetheless it represents
one of the few TD studies carried out among a large
group of travellers visiting the same place and residing
in similar conditions for exactly the same period of time.
Despite the homogeneous circumstances, the variety of
pathogens proved large, the findings varying consider-
ably between individual travellers.
The results of this investigation further attest to the
need to improve routine diagnostics of TD. While
merely 26% of our travellers having the disease (assum-
ing that all EIEC/Shigella had been Shigella spp.) would
have obtained a diagnosis using methods prevalent in
routine diagnostics in most countries, the technique we
applied revealed a pathogen in 92% of those with on-
going (n = 37) or recently subsided (n = 2) symptoms. In
numerous earlier investigations [3] detecting just one
pathogen in most TD patients, diarrhoeagenic E. coli
(e.g. EAEC or EPEC) were not all examined, and even
half of the stool samples proved negative for bacterial
pathogens [3]. With these results in hand, we face the
dilemma of how to determine the actual role of the vari-
ous pathogens. The clinical characteristics of diseases
caused by the various pathogens should each be re-
examined in larger studies using modern methods.
Conclusions
In the group of travellers to Benin, West Africa, 67% of
contracted TD. EPEC, EAEC and ETEC were the most
common findings with 79% of the cases having a co-
infection. As modern diagnostics reveals in most patients a
multitude of pathogens, the role of each pathogen should
be re-evaluated.
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